dc.contributor.author | Martín Guerrero, Idoia | |
dc.contributor.author | Gutiérrez Camino, Ángela | |
dc.contributor.author | Echebarria Barona, Aizpea Beatriz | |
dc.contributor.author | Astigarraga Aguirre, María Iciar | |
dc.contributor.author | García de Andoin Barandiaran, Nagore | |
dc.contributor.author | Navajas Gutiérrez, Aurora | |
dc.contributor.author | García-Orad Carles, África | |
dc.date.accessioned | 2024-02-05T17:12:19Z | |
dc.date.available | 2024-02-05T17:12:19Z | |
dc.date.issued | 2019-02-06 | |
dc.identifier.citation | Pharmacogenomics Journal 19 : 564–569 (2019) | es_ES |
dc.identifier.issn | 1470-269X | |
dc.identifier.issn | 1473-1150 | |
dc.identifier.uri | http://hdl.handle.net/10810/64653 | |
dc.description.abstract | Vincristine is an important drug of acute lymphoblastic leukemia (ALL) treatment protocols that can cause neurotoxicity. Patients treated with LAL/SHOP protocols often suffer from vincristine-related neurotoxicity in early phases of treatment. A genetic variant in CEP72, a gene involved in vincristine pharmacodynamics, was recently associated with neurotoxicity after prolonged vincristine treatment. This association was not replicated in our Spanish population during induction phase. To test the possibility that other variants in genes involved in vincristine pharmacodynamics were associated with vincristine neuropathy in early phases of the treatment, we evaluated the correlation with toxicity of 24 polymorphisms in 9 key genes in a large cohort of 152 Spanish children with B-ALL homogeneously treated. Results showed no association between any genetic variant in the TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4, MAPT, MIR146a, MIR202 and MIR411 genes and vincristine-related neurotoxicity. These results are in line with the hypothesis that there are different mechanisms causing pheripheral neurotoxicity after prolonged and short-term vincristine treatments. | es_ES |
dc.description.sponsorship | This project was supported by the Basque Government (IT989-16, IT661-13 and 2012111053). AGC was supported by a predoctoral grant from the Basque Government (Programa de Formación de Personal Investigador no doctor). Support by the Spanish National Genotyping Center (CeGen) is gratefully acknowledged. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.title | Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2019, Springer Nature Limited | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41397-019-0081-5 | |
dc.identifier.doi | 10.1038/s41397-019-0081-5 | |
dc.departamentoes | Genética, antropología física y fisiología animal | es_ES |
dc.departamentoeu | Genetika,antropologia fisikoa eta animalien fisiologia | es_ES |